Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.
In: Human Antibodies, Jg. 25 (2017-03-01), Heft 3/4, S. 131-146
academicJournal
Zugriff:
This review serves to highlight approaches that may improve the access of antibody drugs to regions of the brain affected by Alzheimer's Disease. While previous antibody drugs have been unsuccessful in treating Alzheimer's disease, recent work demonstrates that Alzheimer's pathology can be modified if these drugs can penetrate the brain parenchyma with greater efficacy. Research in antibody blood-brain barrier drug delivery predominantly follows one of three distinct directions: (1) enhancing influx with reduced antibody size, addition of Trojan horse modules, or blood-brain barrier disruption; (2) modulating trancytotic equilibrium and/or kinetics of the neonatal Fc Receptor; and (3) manipulation of antibody glycan carbohydrate composition. In addition to these topics, recent studies are discussed that reveal a role of glycan sialic acid in suppressing antibody efflux from the brain. [ABSTRACT FROM AUTHOR]
Copyright of Human Antibodies is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.
|
---|---|
Autor/in / Beteiligte Person: | Finke, John M. ; Banks, William A. |
Zeitschrift: | Human Antibodies, Jg. 25 (2017-03-01), Heft 3/4, S. 131-146 |
Veröffentlichung: | 2017 |
Medientyp: | academicJournal |
ISSN: | 1093-2607 (print) |
DOI: | 10.3233/HAB-160306 |
Schlagwort: |
|
Sonstiges: |
|